http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Biomarkers in pursuit of precision medicine for acute kidney injury: hard to get rid of customs
( Kun-mo Lin ),( Ching-chun Su ),( Jui-yi Chen ),( Szu-yu Pan ),( Min-hsiang Chuang ),( Cheng-jui Lin ),( Chih-jen Wu ),( Heng-chih Pan ),( Vin-cent Wu ) 대한신장학회 2024 Kidney Research and Clinical Practice Vol.43 No.4
Traditional acute kidney injury (AKI) classifications, which are centered around semi-anatomical lines, can no longer capture the complexity of AKI. By employing strategies to identify predictive and prognostic enrichment targets, experts could gain a deeper comprehension of AKI’s pathophysiology, allowing for the development of treatment-specific targets and enhancing individualized care. Subphenotyping, which is enriched with AKI biomarkers, holds insights into distinct risk profiles and tailored treatment strategies that redefine AKI and contribute to improved clinical management. The utilization of biomarkers such as N-acetyl-β-D-glucosaminidase, tissue inhibitor of metalloprotease-2·insulin-like growth factor-binding protein 7, kidney injury molecule-1, and liver fatty acid-binding protein garnered significant attention as a means to predict subclinical AKI. Novel biomarkers offer promise in predicting persistent AKI, with urinary motif chemokine ligand 14 displaying significant sensitivity and specificity. Furthermore, they serve as predictive markers for weaning patients from acute dialysis and offer valuable insights into distinct AKI subgroups. The proposed management of AKI, which is encapsulated in a structured flowchart, bridges the gap between research and clinical practice. It streamlines the utilization of biomarkers and subphenotyping, promising a future in which AKI is swiftly identified and managed with unprecedented precision. Incorporating kidney biomarkers into strategies for early AKI detection and the initiation of AKI care bundles has proven to be more effective than using care bundles without these novel biomarkers. This comprehensive approach represents a significant stride toward precision medicine, enabling the identification of high-risk subphenotypes in patients with AKI.
Chen-Ying Hung,Yu-Cheng Hsieh,Jin-Long Huang,Ching-Heng Lin,Tsu-Juey Wu 대한심장학회 2014 Korean Circulation Journal Vol.44 No.4
Atrial fibrillation (AF) is the most common arrhythmia and is associated with increased cardiovascular morbidity and mortality. The anti-arrhythmic effect of statins on AF prevention appears to be highly significant in most clinical studies. However, some discrepancies do existamong different clinical studies. Different clinical settings and types of stains used may explain these differences between trials. The CHADS 2and CHA 2 DS 2 VASc scoring systems have been used for stroke risk stratification in AF patients. The recent study suggested that thesescores can also be used to guide statin therapy for AF prevention. Patients with higher scores had a higher risk of developing AF and gained morebenefits from statins therapy than those with lower scores. This review article focused on the ability of these scores to predict AF preventionby statins.